Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Cancer Biology & Therapy|January 30, 2013
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trialJeffrey R Infante, Hendrik-Tobias Arkenau, Johanna C Bendell, et al.
Clinical Advances in Hematology & Oncology : H&O|September 25, 2010
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancerDavid R Spigel, F Anthony Greco, David Waterhouse, et al.
Antimicrobial Agents and Chemotherapy|May 3, 2017
Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary TuberculosisDerek J Sloan, Andrew D McCallum, Alessandro Schipani, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2018
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153David Waterhouse, Leora Horn, Craig Reynolds, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|September 23, 2021
Assessment of HDR brachytherapy-replicating prostate radiotherapy planning for tomotherapy, cyberknife and VMATRomena de Chavez, Garry Grogan, Ben Hug, et al.
JCO Oncology Practice|September 20, 2022
Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic CancerRachel B Jimenez, Caroline Schenkel, Laura A Levit, et al.
The Patient|August 22, 2018
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance TherapySuzanne McMullen, Lisa M Hess, Edward S Kim, et al.
Parasitology|August 28, 2014
Diagnostics for schistosomiasis in Africa and Arabia: a review of present options in control and future needs for eliminationJ Russell Stothard, Michelle C Stanton, Amaya L Bustinduy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancerJohn Rinehart, Alex A Adjei, Patricia M Lorusso, et al.
Cancer Medicine|January 10, 2014
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancerAndres Forero-Torres, Jeffrey R Infante, David Waterhouse, et al.
Pageof 7